News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
243,570 Results
Type
Article (13597)
Company Profile (22)
Press Release (229948)
Multimedia
Podcasts (13)
Webinars (2)
Section
Business (71472)
Career Advice (1118)
Deals (14455)
Drug Delivery (40)
Drug Development (34589)
Employer Resources (47)
FDA (6634)
Job Trends (5811)
News (125536)
Policy (10350)
Tag
Academia (765)
Accelerated approval (6)
Adcomms (7)
Allergies (60)
Alliances (11301)
ALS (68)
Alzheimer's disease (614)
Antibody-drug conjugate (ADC) (93)
Approvals (6760)
Artificial intelligence (178)
Autoimmune disease (25)
Automation (13)
Bankruptcy (111)
Best Places to Work (4936)
BIOSECURE Act (4)
Biosimilars (84)
Biotechnology (21)
Bladder cancer (89)
Brain cancer (29)
Breast cancer (269)
Cancer (2033)
Cardiovascular disease (157)
Career advice (892)
Career pathing (11)
CAR-T (95)
CDC (7)
Cell therapy (261)
Cervical cancer (20)
Clinical research (30791)
Collaboration (616)
Compensation (388)
Complete response letters (5)
COVID-19 (1034)
CRISPR (32)
C-suite (160)
Cystic fibrosis (48)
Data (2337)
Depression (39)
Diabetes (207)
Diagnostics (2360)
Digital health (11)
Diversity (1)
Diversity, equity & inclusion (13)
Drug discovery (76)
Drug pricing (46)
Drug shortages (12)
Duchenne muscular dystrophy (99)
Earnings (52199)
Editorial (16)
Employer branding (10)
Employer resources (43)
Events (34714)
Executive appointments (409)
FDA (7907)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (1)
Frontotemporal dementia (7)
Funding (598)
Gene editing (76)
Generative AI (9)
Gene therapy (202)
GLP-1 (495)
Government (1553)
Grass and pollen (4)
Guidances (309)
Healthcare (6854)
HIV (26)
Huntington's disease (15)
IgA nephropathy (31)
Immunology and inflammation (93)
Immuno-oncology (5)
Indications (28)
Infectious disease (1153)
Inflammatory bowel disease (66)
Inflation Reduction Act (4)
Influenza (63)
Intellectual property (62)
Interviews (196)
IPO (8509)
IRA (11)
Job creations (1186)
Job search strategy (772)
Kidney cancer (11)
Labor market (31)
Layoffs (190)
Leadership (8)
Legal (2108)
Liver cancer (46)
Longevity (5)
Lung cancer (330)
Lymphoma (167)
Machine learning (11)
Management (11)
Manufacturing (227)
MASH (59)
Medical device (4965)
Medtech (4972)
Mergers & acquisitions (6447)
Metabolic disorders (533)
Multiple sclerosis (69)
NASH (11)
Neurodegenerative disease (72)
Neuropsychiatric disorders (24)
Neuroscience (1046)
NextGen: Class of 2025 (2071)
Non-profit (1537)
Now hiring (30)
Obesity (278)
Opinion (75)
Ovarian cancer (52)
Pain (70)
Pancreatic cancer (78)
Parkinson's disease (112)
Partnered (8)
Patents (142)
Patient recruitment (110)
Peanut (29)
People (8718)
Pharmaceutical (11)
Pharmacy benefit managers (5)
Phase I (8255)
Phase II (13278)
Phase III (11795)
Pipeline (1833)
Policy (53)
Postmarket research (1211)
Preclinical (2816)
Press Release (15)
Prostate cancer (109)
Psychedelics (19)
Radiopharmaceuticals (102)
Rare diseases (248)
Real estate (1340)
Recruiting (19)
Regulatory (8126)
Reports (24)
Research institute (785)
Resumes & cover letters (207)
Rett syndrome (8)
RNA editing (2)
RSV (35)
Schizophrenia (68)
Series A (88)
Series B (69)
Service/supplier (3)
Sickle cell disease (34)
Special edition (10)
Spinal muscular atrophy (84)
Sponsored (13)
Startups (1145)
State (1)
Stomach cancer (6)
Supply chain (48)
Tariffs (21)
The Weekly (13)
Vaccines (430)
Venture capital (32)
Weight loss (186)
Women's health (19)
Worklife (9)
Date
Today (3)
Last 7 days (280)
Last 30 days (1131)
Last 365 days (18680)
2025 (12855)
2024 (16897)
2023 (16187)
2022 (20646)
2021 (20272)
2020 (19028)
2019 (16794)
2018 (12749)
2017 (11970)
2016 (10566)
2015 (12716)
2014 (9228)
2013 (7262)
2012 (7941)
2011 (8061)
2010 (7267)
Location
Africa (319)
Alabama (23)
Alaska (2)
Arizona (67)
Arkansas (5)
Asia (15700)
Australia (2399)
California (4850)
Canada (1402)
China (449)
Colorado (198)
Connecticut (264)
Delaware (169)
Europe (34974)
Florida (601)
Georgia (132)
Hawaii (2)
Idaho (17)
Illinois (374)
India (15)
Indiana (210)
Iowa (8)
Japan (191)
Kansas (48)
Kentucky (9)
Louisiana (9)
Maine (42)
Maryland (537)
Massachusetts (3510)
Michigan (99)
Minnesota (222)
Mississippi (2)
Missouri (57)
Montana (8)
Nebraska (4)
Nevada (55)
New Hampshire (28)
New Jersey (1394)
New Mexico (8)
New York (1271)
North Carolina (539)
North Dakota (3)
Northern California (2195)
Ohio (106)
Oklahoma (5)
Oregon (13)
Pennsylvania (873)
Puerto Rico (9)
Rhode Island (14)
South America (465)
South Carolina (13)
Southern California (1832)
Tennessee (62)
Texas (756)
United States (16870)
Utah (109)
Virginia (122)
Washington D.C. (32)
Washington State (444)
West Virginia (3)
Wisconsin (64)
243,570 Results for "5".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
C-suite
Novo Nordisk Names New Leader, Cuts 2025 Sales Guidance By 5%
In a surprise double announcement Tuesday, Novo reduced sales guidance by 5%—attributing the change to slowed growth of its semaglutide franchise in the U.S.—and named current international operations head Maziar Mike Doustdar as its new president and CEO.
July 29, 2025
·
2 min read
·
Heather McKenzie
Venture capitalists
The Top 5 Most Active Corporate VCs in Pharma
BioSpace
examines the busiest corporate venture capital arms in the pharmaceutical industry. Novo Holdings, which made headlines last year with its $16.5 billion Catalent buy, topped the list.
May 21, 2025
·
5 min read
·
Annalee Armstrong
FDA
5 Companies Caught on a Carousel of FDA Confusion
Amid an unprecedented turnover in leadership at the FDA and mass layoffs of staff, communication has crumbled and uncertainty runs rampant, leaving small and medium biopharma companies without a clear path forward for their therapies.
September 8, 2025
·
8 min read
·
Heather McKenzie
Press Releases
Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection
September 10, 2025
·
3 min read
Obesity
Weight-Loss Wasteland: 5 Obesity Assets That Failed
The mad rush for safe and effective obesity drugs has winners—including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy—and losers. Here are five molecules that never made it to the market.
August 25, 2025
·
9 min read
·
Tristan Manalac
Alzheimer’s disease
5 Alzheimer’s Readouts To Watch
These five upcoming data drops could usher in more effective and convenient therapies for Alzheimer’s disease and open up novel pathways of action to treat the memory-robbing illness.
July 28, 2025
·
8 min read
·
Tristan Manalac
Press Releases
Aethlon Medical Announces Pricing of $4.5 Million Public Offering
September 5, 2025
·
5 min read
Press Releases
Mallia sets strategic course for future and completes €5.5 million financing
June 5, 2025
·
1 min read
Cardiovascular disease
Novartis Doubles Down on Argo Pact With Fresh $5.2B Commitment
Novartis and Argo Biopharma go back to January 2024, when the pharma first bet up to $4.165 billion across two RNAi agreements targeting cardiovascular diseases.
September 3, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Longeveron Announces Up To $17.5 Million Public Offering
August 11, 2025
·
7 min read
1 of 24,357
Next
